Leading Indian drug company Biocon today countered in the Delhi High Court the allegation of Novartis that it had infringed upon the patent right of the Swiss pharmaceutical giant over its diabetes drug Galvus.
The Indian drug manufacturer told the high court that it was not manufacturing the drug for commercial use and was seeking regulatory approval from the outside world.
Senior advocate Pratibha Singh, appearing for Biocon, made the statement before Justice Sanjeev Sachdeva, according to a lawyer appearing in the case.
Novartis has filed the law suit for infringement proceedings alleging that Biocon infringed its patent for its diabetes drug Galvus by launching a generic version of Galvus also known as Vildagliptin. The hearing had taken place on April 28.
In a statement, Biocon has said it respected all valid intellectual property in India.
